Evidence map›Paper›PMID 32958703›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020

Protein Glycosylation: "New-yet-Old" Target for Immunotherapy.

Jaydeep Bhat, Dieter Kabelitz

Abstract readComment
PubMed Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Jaydeep BhatMetabolic Programming, TUM School of Life Sciences Weihenstephan; ZIEL-Institute for Food and Health, Technical University of Munich (TUM), Freising, Germany. bhatvjay24@gmail.com dietrich.kabelitz@uksh.de.ORCID 0000-0002-5123-3125
Dieter KabelitzInstitute of Immunology, Christian-Albrechts-University Kiel & University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany. bhatvjay24@gmail.com dietrich.kabelitz@uksh.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of checkpoint monotherapy in treating cancer has limited success. Post-translational modifications (PTM) of proteins such as glycosylation might have clinical implications due to distinct modifications found in diseases and its regulatory role in the immunometabolic gene expression. Such novel mechanistic targets hold great promise for combined immunotherapy.

Indexed as

NeoplasmsProtein Processing, Post-TranslationalGlycosylationHumansImmunityImmunotherapy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.